"12th Five-Year Plan" blood product supply and strive to "double"

The current shortage of blood products has caused concern for the entire society. This has also become the main topic of the 3rd China Economic Forum Forum on Biopharmaceuticals and National Health. Recently, leaders from various departments including the Ministry of Health, the State Food and Drug Administration, the National Development and Reform Commission, the Ministry of People's Insurance, and the Ministry of Industry and Information Technology attended the forum in Beijing.

Chen Hao, Minister of Health, pointed out in his speech at the forum that blood products are basic and essential special drugs for the treatment of various diseases in modern medicine, and they are scarce and irreplaceable, and they are national strategic resources. At present, the output of blood products still cannot meet the increasing clinical demand. This is not unrelated to the concept of the people. A country's ability to supply pulp represents the advanced level of national productivity and represents a country's moral level. The misunderstanding of "providing pulp = selling blood", "selling blood = poverty = disgracefulness", and "providing pulp = AIDS infection" are important reasons for insufficient domestic raw material plasma collection. Chen Hao encouraged health administrators to take the lead in donating blood.

It is reported that during the “Twelfth Five-Year Plan” period, China will unify the organization and establishment of a blood product production and distribution mechanism, and guide domestic large-scale group production enterprises with strong domestic collection capacity and high plasma utilization rate to strengthen the capacity of plasma station construction. Through the guidance of government policies, the layout of plasma collection stations will be optimized, and the balanced development of the plasma collection work in all regions will be promoted. The construction of plasma stations will be carried out in developed provinces and regions where the demand for blood products is high, plasma supply will be increased, and the safety of national drug supply will be maintained. Implementation of the “multiplication” plan, striving to increase the supply of blood products during the “12th Five-Year Plan” period compared to the end of the “Eleventh Five-Year Plan”; improve system design, establish and improve the national production and circulation mechanism of blood products, and establish national fixed-point production of blood products. Supply system; improve the overall strength of blood product manufacturing enterprises; study the policies for the inclusion of blood products in the national essential drug list; and rationalize the pricing mechanism for blood products.

In response to Minister Chen Wei’s appeal to pay attention to the difficult living environment of hemophilia patients, Taibang Biological Group, a blood product company, decided on the spot that this year’s company’s product eight factors will be donated to the patients through the “Chinese Blood Friends”. Eight factors.